However, a recent study using VE-821 (an analog of VX-970) and a Chk1 inhibitor, in a small number of ovarian cancer lines, concluded that the sensitization profiles of these two compounds can be different[33]. The gene discussed is CHEK1; the disease is ovarian carcinoma.